blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3116546

EP3116546 - COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  20.12.2019
Database last updated on 25.09.2024
FormerExamination is in progress
Status updated on  28.03.2019
FormerRequest for examination was made
Status updated on  16.12.2016
Most recent event   Tooltip20.12.2019Application deemed to be withdrawnpublished on 22.01.2020  [2020/04]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2017/03]
Inventor(s)01 / KUMAR, Rakesh
1250 South Collegeville Road
Collegeville, PA 19426 / US
02 / ROBELL, Kimberly A.
1250 South Collegeville Road
Collegeville, PA 19426 / US
 [2017/03]
Representative(s)Conroy, John
Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
[N/P]
Former [2017/03]Rudge, Sewkian, et al
Novartis Pharma AG
Patent Department
4002 Basel / CH
Application number, filing date15708605.924.02.2015
[2017/03]
WO2015IB51380
Priority number, dateUS201461951640P12.03.2014         Original published format: US 201461951640 P
[2017/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015136398
Date:17.09.2015
Language:EN
[2015/37]
Type: A1 Application with search report 
No.:EP3116546
Date:18.01.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 17.09.2015 takes the place of the publication of the European patent application.
[2017/03]
Search report(s)International search report - published on:EP17.09.2015
ClassificationIPC:A61K45/06, A61K31/4155, A61K31/519, A61P35/00, A61P35/02
[2017/03]
CPC:
A61K31/519 (EP,CN,KR,US); A61K31/4155 (EP,CN,KR,US); A61K45/06 (EP,CN,KR,US);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP);
A61K2300/00 (KR) (-)
C-Set:
A61K31/4155, A61K2300/00 (US,CN,EP);
A61K31/519, A61K2300/00 (CN,EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/03]
TitleGerman:KOMBINATION AUS EINEM BTK-INHIBITOR UND EINEM AKT-INHIBITOR[2017/03]
English:COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR[2017/03]
French:COMBINAISON COMPRENANT UN INHIBITEUR DE BTK ET UN INHIBITEUR D'ATK[2017/03]
Entry into regional phase12.10.2016National basic fee paid 
12.10.2016Designation fee(s) paid 
12.10.2016Examination fee paid 
Examination procedure07.09.2016Amendment by applicant (claims and/or description)
07.09.2016Date on which the examining division has become responsible
12.10.2016Examination requested  [2017/03]
01.04.2019Despatch of a communication from the examining division (Time limit: M04)
13.08.2019Application deemed to be withdrawn, date of legal effect  [2020/04]
09.09.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2020/04]
Fees paidRenewal fee
10.02.2017Renewal fee patent year 03
14.02.2018Renewal fee patent year 04
27.02.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2010088331  (GLAXOSMITHKLINE LLC [US], et al) [A] 1-26,53 * claims 1, 10, 21 *;
 [Y]  - AKINTUNDE AKINLEYE ET AL, "Ibrutinib and novel BTK inhibitors in clinical development", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, (20130819), vol. 6, no. 1, doi:10.1186/1756-8722-6-59, ISSN 1756-8722, page 59, XP021162128 [Y] 1-26,53 * the whole document *

DOI:   http://dx.doi.org/10.1186/1756-8722-6-59
 [Y]  - SPENCER ANDREW ET AL, "Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (201111), Database accession no. PREV201200219138, XP002738038 [Y] 1-26,53 * abstract *
    [ ] - BLOOD, 53RD ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); SAN DIEGO, CA, USA; DECEMBER 10 -13, 2011, (201111), vol. 118, no. 21, ISSN 0006-4971(print), page 808
 [A]  - JAIKRIT BHUTANI ET AL, "Akt inhibitors: mechanism of action and implications for anticancer therapeutics", INFECTIOUS AGENTS AND CANCER, BIOMED CENTRAL LTD, LO, (20131213), vol. 8, no. 1, doi:10.1186/1750-9378-8-49, ISSN 1750-9378, page 49, XP021171563 [A] 1-26,53 * the whole document *

DOI:   http://dx.doi.org/10.1186/1750-9378-8-49
by applicantUS5681835
 US5877219
 US6207716
 US6268391
 WO2008098104
 US7576209
 US2010197754
 WO2011152351
 WO2012020008
 WO2012156334
 WO2012170976
 US2013018032
 WO2013010869
 WO2013010380
 WO2013063401
 WO2013067260
 WO2013081016
 WO2013133367
 WO2013161848
 WO2013191965
    - J. Q. CHEUNG ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1992), vol. 89, pages 9267 - 9271
    - J. Q. CHEUNG ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1996), vol. 93, pages 3636 - 3641
    - NAKATANI ET AL., J. BIOL.CHEM., (1999), vol. 274, pages 21528 - 21532
    - BELLACOSA ET AL., INT. J. CANCER, (1995), vol. 64, pages 280 - 285
    - SUN ET AL., AM. J. PATHOL., (2001), vol. 159, pages 431 - 7
    - LI ET AL., SCIENCE, (1997), vol. 275, pages 1943 - 1947
    - STAMBOLIC ET AL., CELL, (1998), vol. 95, pages 29 - 39
    - SUN ET AL., PROC. NATI. ACAD. SCI. U.S.A., (1999), vol. 96, pages 6199 - 6204
    - LIAW ET AL., NATURE GENETICS, (1997), vol. 16, pages 64 - 67
    - GULDBERG ET AL., CANCER RESEARCH, (1997), vol. 57, pages 3660 - 3663
    - RISINGER ET AL., CANCER RESEARCH, (1997), vol. 57, pages 4736 - 4738
    - PHARMACEUTICAL RESEARCH, (1986), vol. 3, no. 6, page 318
    - MARKMAN ET AL., YALE JOURNAL OF BIOLOGY AND MEDICINE, (1991), vol. 64, page 583
    - MCGUIRE ET AL., ANN. INTEM, MED., (1989), vol. 111, page 273
    - HOLMES ET AL., J. NAT. CANCER INST., (1991), vol. 83, page 1797
    - EINZIG, PROC. AM. SOC. CLIN. ONCOL., pages 20 - 46
    - FORASTIRE, SEM. ONCOL., (1990), vol. 20, page 56
    - WOO, NATURE, (1994), vol. 368, page 750
    - KEARNS, C.M., SEMINARS IN ONCOLOGY, (1995), vol. 3, no. 6, pages 16 - 23
    - KATH, JOHN C., EXP. OPIN. THER. PATENTS, (2000), vol. 10, no. 6, pages 803 - 818
    - SHAWVER ET AL., DDT, (199702), vol. 2, no. 2
    - SINH, S.; COREY, S.J., JOURNAL OF HEMATOTHERAPY AND STEM CELL RESEARCH, (1999), vol. 8, no. 5, pages 465 - 80
    - BOLEN, J.B.; BRUGGE, J.S., ANNUAL REVIEW OF IMMUNOLOGY, (1997), vol. 15, pages 371 - 404
    - SMITHGALL, T.E., JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, (1995), vol. 34, no. 3, pages 125 - 32
    - YAMAMOTO, T.; TAYA, S.; KAIBUCHI, K., JOURNAL OF BIOCHEMISTRY, (1999), vol. 126, no. 5, pages 799 - 803
    - BRODT, P; SAMANI, A.; NAVAB, R., BIOCHEMICAL PHARMACOLOGY, (2000), vol. 60, pages 1101 - 1107
    - MASSAGUE, J.; WEIS-GARCIA, F., CANCER SURVEYS, (1996), vol. 27, pages 41 - 64
    - PHILIP, P.A.; HARRIS, A.L., CANCER TREATMENT AND RESEARCH, (1995), vol. 78, pages 3 - 27
    - LACKEY, K. ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2000), vol. 10, pages 223 - 226
    - MARTINEZ-LACACI, L. ET AL., INT. J. CANCER, (2000), vol. 88, no. 1, pages 44 - 52
    - ABRAHAM, R.T., CURRENT OPINION IN IMMUNOLOGY, (1996), vol. 8, no. 3, pages 412 - 8
    - CANMAN, C.E.; LIM, D.S., ONCOGENE, (1998), vol. 17, no. 25, pages 3301 - 3308
    - JACKSON, S.P., INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, (1997), vol. 29, no. 7, pages 935 - 8
    - ZHONG, H. ET AL., CANCER RES, (2000), vol. 60, no. 6, pages 1541 - 1545
    - SCHAROVSKY, O.G.; ROZADOS, V.R.; GERVASONI, S.I; MATAR, P., JOURNAL OF BIOMEDICAL SCIENCE, (2000), vol. 7, no. 4, pages 292 - 8
    - ASHBY, M.N., CURRENT OPINION IN LIPIDOLOGY, (1998), vol. 9, no. 2, pages 99 - 102
    - BIOCHIM. BIOPHYS. ACTA, (1989), vol. 1423, no. 3, pages 19 - 30
    - GREEN, M.C. ET AL., "Monoclonal Antibody Therapy for Solid Tumors", CANCER TREAT. REV., (2000), vol. 26, no. 4, doi:doi:10.1053/ctrv.2000.0176, pages 269 - 286, XP009019784

DOI:   http://dx.doi.org/10.1053/ctrv.2000.0176
    - "Tyrosine Kinase Signalling in Breast cancer:erbB Family Receptor Tyrosine Kinases", BREAST CANCER RES., (2000), vol. 2, no. 3, pages 176 - 183
    - BREKKEN, R.A. ET AL., "Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice", CANCER RES., (2000), vol. 60, pages 5117 - 5124, XP002340113
    - ROSANIA ET AL., EXP. OPIN. THER. PATENTS, (2000), vol. 10, no. 2, pages 215 - 230
    - BALL ET AL., PROGRESS IN CELL CYCLE RES., (1997), vol. 3, page 125
    - RICHON ET AL., PROC. NAT ACAD. SCI. U.S.A., (2000), vol. 97, no. 18, pages 10014 - 10019
    - VIGUSHIN ET AL., ANTICANCER DRUGS, (200201), vol. 13, no. 1, pages 1 - 13
    - MARKS ET AL., NATURE BIOTECHNOLOGY, (2007), vol. 25, pages 84 - 90
    - STENGER, COMMUNITY ONCOLOGY, (2007), vol. 4, pages 384 - 386
    - VINODHKUMAR ET AL., "Romidepsin, including pharmaceutically acceptable salts thereof", BIOMEDICINE & PHARMACOTHERAPY, (2008), vol. 62, pages 85 - 93
    - "Panobinostat, including pharmaceutically acceptable salts thereof", DRUGS OF THE FUTURE, (2007), vol. 32, no. 4, pages 315 - 322
    - GOTTLICHER ET AL., "Valproic acid, including pharmaceutically acceptable salts thereof", EM BO J., (2001), vol. 20, no. 24, pages 6969 - 6978
    - BALASUBRAMANIAN ET AL., "Mocetinostat (MGCD0103), including pharmaceutically acceptable salts thereof", CANCER LETTERS, (2009), vol. 280, pages 211 - 221
    - BERTRAND, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (2010), vol. 45, pages 2095 - 2116
    - ADAMS J; KAUFFMAN M, "Bortezomib (Velcade@), including pharmaceutically acceptable salts thereof", CANCER INVEST, (2004), vol. 22, no. 2, pages 304 - 11
    - BOUMA ET AL., "Disulfiram, including pharmaceutically acceptable salts thereof", J. ANTIMICROB. CHEMOTHER., (1998), vol. 42, no. 6, pages 817 - 20
    - WILLIAMSON ET AL., "Epigallocatechin gallate (EGCG), including pharmaceutically acceptable salts thereof", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (200612), vol. 118, no. 6, pages 1369 - 74
    - FELING, "Salinosporamide A, including pharmaceutically acceptable salts thereof", ANGEW. CHEM. INT. ED. ENGL., (2003), vol. 42, no. 3, pages 355 - 7
    - KUHN DJ ET AL., "Carfilzomib, including pharmaceutically acceptable salts thereof", BLOOD, (2007), vol. 110, pages 3281 - 3290
    - JIAW ET AL., "17-AAG(Geldanamycin), including pharmaceutically acceptable salts thereof", BLOOD, (20030901), vol. 102, no. 5, pages 1824 - 32
    - LEE ET AL., "Radicicol, including pharmaceutically acceptable salts thereof", MOL CELL ENDOCRINOL., (2002), vol. 188, pages 47 - 54
    - D. A. TENNANT, NATURE REVIEWS, (2010), page 267
    - P. LEDER, CANCER CELL, (2006), vol. 9, page 425
    - ALII ET AL., ONCOGENE, (2005), vol. 24, pages 39 - 46
    - CHOU; TALALAY, ADVANCES IN ENZYME REGULATION, (1984), vol. 22, pages 37 - 55
    - BERENBAUM, MC, ADV. CANCER RESEARCH, (1981), vol. 35, pages 269 - 335
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.